Search results for "PROGESTERONE"

showing 10 items of 188 documents

Tumeurs localisées du sein triple négatives en 2016 : définitions et prise en charge

2016

Triple-negative breast cancer (TN), as defined by the triple negativity in immunohistochemistry: the absence of estrogen receptor, progesterone receptor and the absence of overexpression or amplification of HER2, corresponds to 15 % of invasive breast cancers. This is a very heterogeneous group of tumors both at the genomic and transcriptomic level and at morphological, clinical and prognostic level. Although there are some good prognosis forms, the majority of TN tumors is characterized by a poor prognosis with a greater frequency of visceral metastases and a maximum risk of relapse in the first two years after diagnosis. Systemic adjuvant treatment with chemotherapy is almost always indic…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentObstetrics and GynecologyEstrogen receptorGeneral Medicinemedicine.diseaseSystemic therapyOncologic surgery03 medical and health sciences0302 clinical medicineBreast cancerReproductive Medicine030220 oncology & carcinogenesisInternal medicineProgesterone receptormedicineImmunohistochemistry030212 general & internal medicinebusinessAdjuvantGynécologie Obstétrique & Fertilité
researchProduct

Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer

1993

Immunohistochemistry of Estrogen Receptor (ER) and Progesterone Receptor (PR) has been performed in 687 cases of human breast cancer. The staining results have been compared by (1) computer-assisted image analysis (QIC Score) and (2) subjective grading of the cryostat sections ("German" IRS). Tumors without or with only weak ER or PR content may be distinguished by both methods from tumors with a high receptor content. The QIC Score values belonging to the intermediate IRS grades are distributed over a wide range, but no negative cases were found in these categories. It is concluded from our results that subjective grading of the slides is a simple, rapid and useful method for the determina…

Oncologymedicine.medical_specialtyPathologybusiness.industrymedicine.drug_classEstrogen receptorCell Biologymedicine.diseasePathology and Forensic MedicineBreast cancerEstrogenInternal medicineProgesterone receptorMedicineImmunohistochemistrybusinessReceptorGrading (tumors)Human breastPathology - Research and Practice
researchProduct

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

2015

International audience; We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not …

Oncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsTriple Negative Breast NeoplasmsLower riskBreast cancerTrastuzumabInternal medicinemedicineHumansNeoplasm Metastasisskin and connective tissue diseasesAgedNeoplasm StagingGynecologyregisterbusiness.industryCarcinoma Ductal BreastAge FactorsAbsolute risk reductionhormone receptorsCancerTriple Negative Breast NeoplasmsMiddle AgedTrastuzumabHER2 receptorsPrognosismedicine.diseaseMetastatic breast cancerConfidence interval3. Good healthpopulation-basedCarcinoma LobularReceptors EstrogenOncologyLinear ModelsFemalemetastatic breast cancernet survivalReceptors Progesteronebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Preliminary Results of Two Eortc Randomized Trials in Previously Untreated Patients with Advanced T3 — T4 Prostatic Cancer

1983

At the end of 1976 and the beginning of 1977 respectively, the EORTC Genito-Urinary Tract Cancer Cooperative Group started two randomized phase III protocols in previously untreated patients with advanced T3–4 prostatic cancer (1–3). The first trial, 30762, compared Stilboestrol and Estracyt, while the second, 30761, was a randomized comparison of Stilboestrol, Cyproterone Acetate and Medroxyprogesterone Acetate. Both trials have now been closed to patient entry and the principal endpoints of the studies analyzed. This paper will present the interim results which have emerged from these two studies.

Oncologymedicine.medical_specialtybusiness.industryBone metastasisCyproterone acetateCancermedicine.diseaselaw.inventionCardiovascular deathchemistry.chemical_compoundchemistryRandomized controlled triallawInternal medicinemedicineMedroxyprogesterone acetateCooperative groupbusinessmedicine.drug
researchProduct

Second-Line Endocrine Treatment

1988

It was a milestone of cancer therapy in general when Huggins et al. [1] in 1941 first reported the beneficial clinical effects of bilateral orchiectomy in patients with prostate cancer, and the use of castration or estrogens as standard therapy remained the first- line treatment for many years. It was furthermore the beginning of a development which, over the following decades, led to the manipulation of testicular androgen synthesis and to attempts to eliminate other possible sources of male hormones.

Oncologymedicine.medical_specialtybusiness.industryCyproterone acetatemedicine.diseasechemistry.chemical_compoundProstate cancerAndrogen synthesisCastrationSecond linechemistryInternal medicinemedicineEndocrine systemMedroxyprogesterone acetatebusinessHormonemedicine.drug
researchProduct

Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.

2003

Objective To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT) on serum homocysteine levels in postmenopausal women. Design An open, prospective, controlled study. Seventy-five healthy postmenopausal women were recruited as eligible for the study. Fifty women seeking HRT were randomized to receive continuous 17beta-estradiol, either by oral (2 mg daily; n = 25) or transdermal (50 microg daily; n = 25) administration, plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle. Twenty-five women unwilling to receive hormone treatment received only calcium supplementation, representing the control group. Fasting blood samples were analyzed at baselin…

Oralmedicine.medical_specialtyAdministration CutaneouHomocysteineEstronemedicine.medical_treatmentHRTAdministration OralEstroneDydrogesteroneAdministration CutaneousGastroenterologylaw.inventionchemistry.chemical_compoundFollicle-stimulating hormoneRandomized controlled triallawReference ValuesInternal medicineMedicineHumansReference ValueProspective StudiesProspective cohort studyHomocysteineTransdermalEstradiolProgesterone Congenersbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyHormone replacement therapy (menopause)Progesterone CongenerMiddle AgedHomocysteine; HRT; TransdermalPostmenopauseProspective StudieEndocrinologychemistryDydrogesteroneDrug Therapy CombinationFemaleFollicle Stimulating HormonebusinessTransdermalmedicine.drugHumanMenopause (New York, N.Y.)
researchProduct

Reconstruction of Endometrium from Human Endometrial Side Population Cell Lines

2011

Endometrial regeneration is mediated, at least in part, by the existence of a specialized somatic stem cell (SSC) population recently identified by several groups using the side population (SP) technique. We previously demonstrated that endometrial SP displays genotypic, phenotypic and the functional capability to develop human endometrium after subcutaneous injection in NOD-SCID mice. We have now established seven human endometrial SP (hESP) cell lines (ICE 1-7): four from the epithelial and three from the stromal fraction, respectively. SP cell lines were generated under hypoxic conditions based on their cloning efficiency ability, cultured for 12-15 passages (20 weeks) and cryopreserved.…

PathologyAnatomy and PhysiologyCellular differentiationlcsh:MedicineVimentinCell SeparationMice SCIDEndometriumEndometriumMice0302 clinical medicineMice Inbred NODReproductive PhysiologyMolecular Cell Biologylcsh:ScienceSide-Population CellsMedicine(all)0303 health scienceseducation.field_of_study030219 obstetrics & reproductive medicineMultidisciplinaryAgricultural and Biological Sciences(all)biologyStem CellsObstetrics and GynecologyCell DifferentiationAdult Stem Cellsmedicine.anatomical_structurePhenotypeSomatic CellsMedicineFemaleCellular Types/dk/atira/pure/subjectarea/asjc/2700Receptors ProgesteroneAdult stem cellResearch Articlemedicine.medical_specialtyStromal cellPopulationCell Line/dk/atira/pure/subjectarea/asjc/130003 medical and health sciencesSide population/dk/atira/pure/subjectarea/asjc/1100medicineAnimalsHumansRegenerationeducationBiology030304 developmental biologyBiochemistry Genetics and Molecular Biology(all)lcsh:RMesenchymal stem cellEstrogen Receptor alphaReproductive SystemEpithelial CellsMesenchymal Stem CellsMolecular biologyKaryotypingbiology.proteinlcsh:QStromal CellsStem Cell LinesBiomarkersCytometry
researchProduct

Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients

2014

The importance of inflammation is increasingly noticed in cancer. The aim of this study was to analyze the prognostic influence of pre-operative serum C-reactive protein (CRP) in a cohort of 148 lymph node-negative breast cancer patients. The prognostic significance of CRP level for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) was evaluated using univariate and multivariate Cox regression, also including information on age at diagnosis, tumor size, tumor grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status, proliferation index (Ki67) and molecular subtype, as well as an assessment of the…

PathologyProliferation indexReceptor ErbB-2lcsh:MedicineEstrogen receptorGastroenterologyMetastasisCohort StudiesBasic Cancer ResearchBreast TumorsMedicine and Health SciencesMedicineNeoplasm Metastasislcsh:ScienceImmune ResponseAged 80 and overUnivariate analysisMultidisciplinarybiologyCancer Risk FactorsHazard ratioObstetrics and GynecologyMiddle AgedPrognosisGene Expression Regulation NeoplasticC-Reactive ProteinOncologyReceptors EstrogenFemaleReceptors ProgesteroneResearch ArticleCancer Predisposing Conditions and SyndromesAdultmedicine.medical_specialtyImmunologyBreast NeoplasmsDisease-Free SurvivalBreast cancerInternal medicineBreast CancerHumansImmune EvasionAgedCell ProliferationProportional Hazards ModelsInflammationGenome Humanbusiness.industryProportional hazards modelGene Expression Profilinglcsh:RC-reactive proteinImmunityBiology and Life SciencesCancers and NeoplasmsCancermedicine.diseaseKi-67 Antigenbiology.proteinWomen's Healthlcsh:QClinical ImmunologyLymph NodesbusinessPLoS ONE
researchProduct

Metastatic seeding of colon adenocarcinoma manifesting as synchronous breast and chest wall localization: report of a case.

2011

Colon carcinoma rarely metastasizes to the breast and it is usually associated with a poor prognosis. Even rarer is metastatic seeding of colon cancer cells in an intramammary location after surgery. Including a primary breast malignancy in the differential diagnosis of such cases is mandatory. We report a rare case of double seeding implantation of colon adenocarcinoma inside the breast parenchyma and intercostal muscles 6 years after resection of a pulmonary metastasis from colon adenocarcinoma. The metastasis was revealed by the presence of bone metaplasia in the intercostal muscles. We discuss how negative immunostaining for estrogen receptors, progesterone receptors, and HER-2, along w…

Pathologymedicine.medical_specialtyColorectal cancerReceptor ErbB-2Estrogen receptorNeoplasm SeedingBreast NeoplasmsIntercostal MusclesSettore MED/08 - Anatomia PatologicaAdenocarcinomaBone and BonesMetastasisCytokeratinNeoplasm SeedingMetaplasiamedicineCarcinomaHumansAgedMetaplasiabusiness.industryGeneral MedicineThoracic Neoplasmsmedicine.diseasedigestive system diseasesSettore MED/18 - Chirurgia GeneraleMetastatic seeding colon adenocarcinoma breast cdx2ck20 ck7Receptors EstrogenColonic NeoplasmsSurgeryFemaleDifferential diagnosismedicine.symptombusinessReceptors ProgesteroneSurgery today
researchProduct

CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome

2007

Aims: CD1a is a molecule belonging to the highlyconserved group of CD1 proteins. Its expression indendritic cells is related to the presentation of tumour-derived glycolipid antigens to T cells and, consequently,the development of a successful antitumour response.The aim was to investigate the presence of CD1a+ cellsin both primary tumours and lymph nodes (LN) ofa series of 35 invasive ductal carcinomas by bothimmunohistochemistry and reverse transcription-poly-merase chain reaction.Methods and results: CD1a antigen was more expressedin N0 than N1 breast cancer (P < 0.0001) in bothprimary lesions and LN metastases and correlatedpositively and significantly with oestrogen (ER) (P =0.0025) and…

Pathologymedicine.medical_specialtyHistologybusiness.industryCancerGeneral MedicineDendritic cellDuctal carcinomamedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureBreast cancerProgesterone receptormedicineCarcinomaskin and connective tissue diseasesAntigen-presenting cellbusinessLymph nodeHistopathology
researchProduct